Wall Street consensus ratings on Emergent BioSolutions generally lean toward a cautious hold or speculative buy, as institutional analysts weigh its attractive deep-value entry price against ongoing operational hurdles. While some target upside projections anticipate recovery from government biodefense contracts, others advise waiting for clearer signs of sustained net profitability and margin stabilization.